Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares reached a new 52-week low during trading on Friday . The company traded as low as $37.18 and last traded at $37.80, with a volume of 15660 shares. The stock had previously closed at $57.67.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZLDPF. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday. Finally, BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Four research analysts have rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Zealand Pharma A/S Stock Down 36.6%

The company has a market capitalization of $2.60 billion, a PE ratio of 2.67 and a beta of 0.75. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $64.96 and a two-hundred day simple moving average of $70.77.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. Research analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.